SOPHiA GENETICS (SOPH) Cash & Equivalents (2020 - 2026)

SOPHiA GENETICS has disclosed Cash & Equivalents across 7 years of filings, most recently posting $107.7 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 13.54% year-over-year to $107.7 million; the TTM figure through Jun 2026 stood at $107.7 million (up 13.54% YoY), while the FY2025 annual figure was $70.3 million, down 12.39% from the prior year.
• Cash & Equivalents came in at $107.7 million for Q2 2026 at SOPHiA GENETICS, up from $65.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $182.9 million in Q1 2022 to a low of $65.4 million in Q1 2026.
• Average Cash & Equivalents over 5 years is $117.8 million, with a median of $106.5 million recorded in 2024.
• Year-over-year, Cash & Equivalents jumped 321.07% in 2022 and plunged 35.47% in 2024.
• Over 5 years, Cash & Equivalents stood at $161.3 million in 2022, then decreased by 23.59% to $123.3 million in 2023, then sank by 34.91% to $80.2 million in 2024, then slipped by 12.39% to $70.3 million in 2025, then surged by 53.17% to $107.7 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $107.7 million in Q2 2026, $65.4 million in Q1 2026, and $70.3 million in Q4 2025.